US – SHL Medical has revealed plans to build a new manufacturing site in the US, in response to the growing market demand for its autoinjector product portfolio.
SHL Medical is a world-leading solutions provider in the design, development, and manufacturing of advanced delivery devices such as autoinjectors, pen injectors, and innovative specialty delivery systems for large-volume and high-viscosity formulations.
The company offers final assembly, labeling, and packaging solutions for drug delivery devices, and also provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
The decision stems from SHL’s strategic assessments in extending its production to North America.
The new US site will be located in North Charleston, South Carolina, and will boast approximately 25,000 m2 (270,000 ft2).
With initial investments of US$ 90 million, SHL is expected to create an estimate of 165 local employment opportunities. Operations are expected to launch by 2024.
The South Carolina site will be an advanced facility with medical device injection molding and fully automated assembly capabilities.
Together with SHL’s current final assembly, labeling, and packaging operations in Deerfield Beach, Florida, the expanded manufacturing capabilities in the US will further fortify SHL’s offerings in delivering comprehensive services to its partners.
In 2019, SHL developed a long-term strategy in response to the growing autoinjector demand and to meet future manufacturing needs.
The announcement of the new US operation aligns with the company’s ongoing expansion, including a new Swiss site already being announced.
The new production site in the US, which is to be realized preferentially and accelerated, will offer fully automated production facilities and a flexible supply chain with reduced distance to main markets.
Chairman and CEO Ulrich Faessler said: “Demand for SHL’s products has increased significantly. Therefore, we are speeding up our plans for a new plant in the US.
“Similar to our upcoming European site in Zug, Switzerland, the US site will be a state-of-the-art, fully automated site.
Faessler added that the expansion signifies SHL’s pledge to its advanced manufacturing strategy that will support sustainability goals; and, at the same time, risk-mitigate supply chain disturbances through closer production with its customers.
The project further supports SHL’s customers with one-stop-shop capabilities, providing high-quality drug delivery systems to the end-users – the patients, notes Faessler.
Liked this article? Subscribe to our regular email newsletters with the latest news insights from Africa and the World’s packaging and printing industry. SUBSCRIBE HERE.
